Last edition
News about "Inflammatory Bowel Disease Center "
Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis
Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.
Inflammatory Bowel Disease Center | 28/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members